What Can We Expect From BMY’s Q2 Earnings?
Bristol-Myers Squibb (NYSE: BMY) will report its Q2 earnings on July 28,2016. We expect blood thinning drug Eliquis, its Oncology division and Hepatitis C franchise could help boost its earnings. Here are the reasons why we think so.
- Should You Pick Bristol Myers Squibb Stock After A 30% Fall Last Year And Q4 Beat?
- Is Bristol Myers Squibb Stock Undervalued At $50?
- Will Bristol Myers Squibb Stock Rebound To Its Pre-Inflation Shock Level of $80?
- Which Stock Is A Better Healthcare Pick – Bristol Myers Squibb Or HCA?
- Will Bristol Myers Squibb Stock Rise Post Q1?
- Is Bristol Myers Squibb Stock A Better Pick Over Its Industry Peer?
Source:
Sec Filings
Have more questions about Bristol-Myers Squibb? See the links below.
- Three Things To Watch Out For Bristol-Myers Squibb This Year
- What’s Bristol-Myers Squibb’s Revenue And Earnings Breakdown?
- What’s Bristol-Myers Squibb’s Fundamental Value Based On Expected 2015 Results?
- How Has Bristol-Myers Squibb’s Revenue Composition Changed Over The Last 5 Years
- By What Percentage Can Bristol-Myers Squibb’s Revenue & EBITDA Grow In The Next 3 Years?
- How Much Revenues Can Bristol-Myers Squibb’s Phase 3 Pipeline Add By 2020?
- Why We Are Bullish On Bristol-Myers Squibb
- Bristol-Myers Squibb Did Well In 2015, And New Drugs Could Keep The Momentum Going
Notes:
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)